[go: up one dir, main page]

MX2007009591A - Metodos para disposicion mejorada de farmacos. - Google Patents

Metodos para disposicion mejorada de farmacos.

Info

Publication number
MX2007009591A
MX2007009591A MX2007009591A MX2007009591A MX2007009591A MX 2007009591 A MX2007009591 A MX 2007009591A MX 2007009591 A MX2007009591 A MX 2007009591A MX 2007009591 A MX2007009591 A MX 2007009591A MX 2007009591 A MX2007009591 A MX 2007009591A
Authority
MX
Mexico
Prior art keywords
methods
drug disposition
improving drug
improving
iron chelator
Prior art date
Application number
MX2007009591A
Other languages
English (en)
Inventor
Gerhard Gross
Gian P Camenisch
Hanspeter Nick
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2007009591A publication Critical patent/MX2007009591A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invencion proporciona un metodo para mejorar la biodisponibilidad, de preferencia biodisponibilidad oral, y/o disposicion de farmaco, por ejemplo penetracion del cerebro, de un quelante de hierro, dicho metodo comprende co-administrar a un mamifero, especialmente un ser humano, en necesidad del tratamiento, una combinacion de un quelante de hierro y un inhibidor de proteina de eflujo.
MX2007009591A 2005-02-10 2006-02-08 Metodos para disposicion mejorada de farmacos. MX2007009591A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65168405P 2005-02-10 2005-02-10
PCT/EP2006/001118 WO2006084683A1 (en) 2005-02-10 2006-02-08 Methods for improving drug disposition

Publications (1)

Publication Number Publication Date
MX2007009591A true MX2007009591A (es) 2007-09-12

Family

ID=36084421

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007009591A MX2007009591A (es) 2005-02-10 2006-02-08 Metodos para disposicion mejorada de farmacos.

Country Status (11)

Country Link
US (2) US20080187510A1 (es)
EP (1) EP1853235A1 (es)
JP (1) JP2008530043A (es)
KR (1) KR20070101314A (es)
CN (1) CN101111237A (es)
AU (1) AU2006212417A1 (es)
BR (1) BRPI0607058A2 (es)
CA (1) CA2597332A1 (es)
MX (1) MX2007009591A (es)
RU (1) RU2007133712A (es)
WO (1) WO2006084683A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8829198B2 (en) * 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
EP2026800A1 (en) * 2006-05-09 2009-02-25 Novartis AG Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
WO2008065123A2 (en) 2006-11-29 2008-06-05 Novartis Ag Polymorphic forms of deferasirox ( icl670a)
EP1927591A1 (en) * 2006-11-29 2008-06-04 Novartis AG Polymorphic Forms of Deferasirox (ICL670)
WO2009111611A2 (en) 2008-03-05 2009-09-11 Proteotech Inc. Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
WO2014168255A1 (ja) * 2013-04-12 2014-10-16 国立大学法人京都大学 巨核球の成熟化促進物質
US12419884B2 (en) 2018-08-06 2025-09-23 Brigham Young University Compositions and methods for treating iron overload

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8528983D0 (en) * 1985-11-25 1986-01-02 Ciba Geigy Ag Use of chelating agents
EP0227593A1 (en) * 1985-11-25 1987-07-01 The Hospital For Sick Children Use of chelating agents
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition

Also Published As

Publication number Publication date
RU2007133712A (ru) 2009-03-20
US20080187510A1 (en) 2008-08-07
BRPI0607058A2 (pt) 2009-08-04
CA2597332A1 (en) 2006-08-17
US20090306160A1 (en) 2009-12-10
KR20070101314A (ko) 2007-10-16
CN101111237A (zh) 2008-01-23
JP2008530043A (ja) 2008-08-07
WO2006084683A1 (en) 2006-08-17
EP1853235A1 (en) 2007-11-14
AU2006212417A1 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
UA118645C2 (uk) Спосіб комбінованої терапії раку наночастинками, що містять рапаміцин і альбумін
IL179515A0 (en) Method of administering and using vegf inhibitors for the treatment of human cancer
NZ593474A (en) Compositions and methods for treatment of celiac disease
IL184047A0 (en) Methods and compositions for treating amyloid-related diseases
SG155163A1 (en) Pharmacokinetically improved compounds
GB0504988D0 (en) Device and method for the treatment of diseased tissue such as tumors
TW200738270A (en) Method of treating depression using a TNFα antibody
EP1906854A4 (en) MEDICAL TREATMENT ELECTRODE ARRANGEMENT AND MEDICAL TREATMENT METHOD
WO2008025020A3 (en) Cd30 binding agents and uses thereof
IL172194A0 (en) Methods and compositions for treating amyloid-related diseases
CA2645871A1 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OXALATE-ASSOCIATED DISEASE
EP1811844A4 (en) METHOD FOR THE DIAGNOSIS AND TREATMENT OF CANCER
WO2006024018A3 (en) Compositions for treating nociceptive pain
IL183079A0 (en) Method and fluorinated compositions for treating amyloid-related diseases
MX2011012015A (es) Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
TW200716224A (en) Method of indentifying therapeutic targets for the treatment of vulvovaginal atrophy
EP1773369A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THE PEPTIDE TREATMENT
TNSN07038A1 (en) Methods for improving bioavailability of a renin inhibitor
EP1968505A4 (en) DEVICES AND METHOD FOR THE TREATMENT OF BONE FRACTURES
MX2007009591A (es) Metodos para disposicion mejorada de farmacos.
TNSN07453A1 (en) Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases
TW200806293A (en) Methods of treatment with CETP inhibitors
WO2008034071A3 (en) Method of identifying patients suitable for high-dose cyclophosphamide treatment
MX2009005247A (es) Metodos para mejorar la biodisponibilidad de un inhibidor de renina.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal